top of page

US-China Rivalry in Biotech: Balancing Security and Collaboration

As the United States and China jostle for dominance in various sectors, the battleground has expanded to include biotechnology. Lawmakers in the US are sounding the alarm over what they perceive as America's lag in biotech competitiveness vis-à-vis China, citing concerns about national security and commercial interests.

However, the debate is complex, with voices cautioning against overzealous restrictions on Chinese companies and emphasizing the potential benefits of collaboration.


Biotechnology holds immense promise, with applications ranging from medical treatments to genetic engineering in agriculture and biomaterials innovation. Recognizing its transformative potential, both the US and China have prioritized investment and development in the biotech sector.


In response to perceived threats, bills have been introduced in the US Congress aimed at barring certain "foreign adversary biotech companies" from engaging with federally funded medical providers, specifically targeting four Chinese-owned firms. However, the Chinese Embassy has criticized these efforts as ideologically biased and warned against discrimination.


Critics of the proposed legislation argue that stringent restrictions on Chinese companies could hinder scientific advancements and impede efforts to address global challenges such as disease prevention and food security. Supporters of the bills, however, contend that such measures are essential for safeguarding US interests, particularly in light of potential national security risks.


The National Security Commission on Emerging Biotechnology asserts that restrictions would protect sensitive data and prevent unfair competition from Chinese entities, highlighting the dual-use nature of biotechnology and its implications for military capabilities.


The US government's approach to biotech reflects broader strategic considerations, with the Biden administration prioritizing technological leadership and economic competitiveness. Meanwhile, China has outlined plans to bolster its biotech capabilities as part of a broader strategy for technological independence.


Despite concerns about unfair competition and lack of transparency in China's biotech industry, some caution against excessive vilification of Chinese companies. They highlight the importance of distinguishing between competition and unfair practices, emphasizing the need for a nuanced approach.


Central to the debate is the role of specific Chinese firms, such as BGI and WuXi AppTec, which have been singled out for their alleged ties to the Chinese military and concerns about data security. While these companies deny posing security threats, suspicions persist, fueled by allegations of state subsidies and government collaboration.


In navigating the complexities of the US-China biotech rivalry, striking a balance between security imperatives and collaborative potential is crucial. As both countries vie for technological supremacy, ensuring responsible innovation and ethical governance should remain paramount, with a recognition of the shared global stakes in biotechnology's future.



bottom of page